This decision was endorsed after it was deemed safe and effective based on an ongoing clinical trial involving 4,526 participants.
The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years.
It is given as three injections in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.
This presentation is designed for this new age group and given at a lower dose than those used in individuals aged 5 to 11 years (3 micrograms compared with 10 micrograms).
The Comirnaty COVID vaccine has met the MHRA's required safety, quality, and effectiveness standards to be authorized for use in this age group.
Price Action: PFE shares are down 2.38% at $49.53, and BNTX shares are down 3.96% at $160.10 on the last check Monday.
Photo via Wikimedia Commons
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.